Health Canada has issued the first Certificates of Supplementary Protection (CSPs) against the following approvals: neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily A/neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily B (Pfizer’s TRUMENBA), letermovir (Merck’s PREVYMIS), and guselkumab (TREMFYA)(see: Register of Certificates of Supplementary Protection). In addition, the CSP application fee as of April 1, 2018 is $9,192.
Related Publications & Articles
-
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More